Additionally, any cardioprotective effect in the EPO and the control group regarding changes in left ventricle ejection fraction (LVEF), left ventricle end-systolic and end-diastolic (LVESV and LVESV), incidence of arrhythmias, cardiac remodeling, major adverse cardiovascular events (MACE), and EPO safety were all assessed. This evidence concerns the gene EPO and cardiac arrhythmia.